(Omacetaxine mepesuccinate (homoharringtonine))


Drug updated on 11/9/2023

Dosage FormInjection (subcutaneous; 3.5 mg)
Drug ClassAntineoplastics
Ongoing and Completed


  • For the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).

Product Monograph / Prescribing Information

Document TitleYearSource
Synribo (omacetaxine mepesuccinate) Prescribing Information.2021Teva Pharmaceuticals USA Inc., North Wales, PA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Chronic myeloid leukemia, version 2.2021.2020Journal of the National Comprehensive Cancer Network
Standard commercial drug formulary prior authorization guidelines - omacetaxine mepesuccinate. 2019Kaiser